Genetic variants of p21 and p27 and pancreatic cancer risk in non-hispanic whites: A case-control study

Pancreas

Volumn 39, Issue 1, 2010, Pages 1-4

  Chen, Jinyun ^a   Amos, Christopher I ^a,b   Merriman, Kelly W ^a   Wei, Qingyi ^a,b   Sen, Subrata ^a,b   Killary, Ann M ^a,b   Frazier, Marsha L ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Case control; P21; P27; Pancreatic cancer; Polymorphisms

Indexed keywords

PROTEIN P21; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; WILD TYPE;

AGED; ALLELES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING;

EID: 74049101515     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181bd51c8     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897-909.
3. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
4. Schor E, da Silva ID, Sato H, et al. P27Kip1 is down-regulated in the endometrium of women with endometriosis. Fertil Steril. 2009;91: 682-686.
5. Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008;10:e19.
6. He G, Kuang J, Huang Z, et al. Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21. Br J Cancer. 2006; 95:1514-1524.
7. Asomaning K, Reid AE, ZhouW, et al. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin Cancer Res. 2008;14: 4010-4015.
8. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in theMDM2promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591-602.
9. Chen J, Li D, Wei C, et al. Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. Clin Cancer Res. 2007;13:3100-3104.
10. Dong M, Ma G, TuW, et al. Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer. World J Gastroenterol. 2005;11:2162-2165.
11. Gayther SA, Song H, Ramus SJ, et al. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 2007;67:3027-3035.
12. Jones JS, Chi X, Gu X, et al. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res. 2004;10:5845-5849.
13. Kibel AS, Suarez BK, Belani J, et al. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 2003;63:2033-2036.
14. Kong S, Wei Q, Amos CI, et al. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst. 2001;93:1106-1108.
15. Ye Y, Yang H, Grossman HB, et al. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer. 2008;112:2467-2474.
16. Chedid M, Michieli P, Lengel C, et al. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene. 1994;9: 3021-3024.
17. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature. 1999;398:160-165.
18. Schondorf T, Eisele L, Gohring UJ, et al. The V109G polymorphism of the p27 gene CDKN1B indicates a worse outcome in node-negative breast cancer patients. Tumour Biol. 2004;25:306-312.
19. Li G, Liu Z, Sturgis EM, et al. Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2005;26:1596-1602.
20. Li G, Sturgis EM, Wang LE, et al. Association between the V109G polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma. Clin Cancer Res. 2004;10: 3996-4002.
21. Keshava C, Frye BL, Wolff MS, et al. Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:127-130.
22. Popanda O, Edler L, Waas P, et al. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer. 2007;55:25-34.
23. Roh JW, Kim JW, Park NH, et al. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol. 2004;93: 499-505.
24. Xi YG, Ding KY, Su XL, et al. p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis. 2004;25:2201-2206.
25. Shih CM, Lin PT, Wang HC, et al. Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res. 2000;91:9-15.
26. Su L, Liu G, Zhou W, et al. No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:174-175.
27. Ma H, Jin G, Hu Z, et al. Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women. Int J Cancer. 2006;119:2173-2178.
28. Harada K, Ogden GR. An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol. 2000;36:3-7.
29. Huppi K, Siwarski D, Dosik J, et al. Molecular cloning, sequencing, chromosomal localization and expression of mouse p21 (Waf1). Oncogene. 1994;9:3017-3020.
30. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13: 1501-1512.
31. Chang BL, Zheng SL, Isaacs SD, et al. A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res. 2004;64:1997-1999.